Comparison of Trigeminal Autonomic Cephalalgias: Cluster Headache vs Paroxysmal Hemicrania vs SUNCT and SUNA vs Hemicrania Continua
Posted on August 04 2023,
| Clinical Features | Cluster Headache | Paroxysmal Hemicrania | SUNCT* & SUNA** | Hemicrania Continua |
|---|---|---|---|---|
| Sex Predominance | Mostly male | Equal male & female | Mostly female | Mostly female |
| Pain Type | Stabbing | Stabbing or pulsating | Stabbing or burning | Varied pain types |
| Pain Severity | Very severe | Very severe | Severe to very severe | Mild to severe |
| Location | Eye or temple | Eye or temple | Eye or temple | Eye, forehead, and/or temple |
| Attack Frequency | 1 every other day to 8 daily | 5 to 40 daily | 1 to 200 daily | Constant with flare ups |
| Attack Duration | 15 mins to 3 hrs | 2 to 30 mins | Seconds to 10 mins | Months to years untreated |
| Autonomic Symptoms? | Yes | Yes | Yes | Yes |
| Agitation? | Yes | Yes | Sometimes | Yes |
| Migraine Features?*** | Yes | Yes | Rarely | Often |
| Triggers | Alcohol | Stress, exercise, alcohol | Touching face | Alcohol |
| Indomethacin Responsive? | No | Yes | No | Yes |
| Acute Treatment | Triptans, oxygen | None | Lidocaine IV for severe | None |
| Preventive Treatment | Verapamil, corticosteroids, galcanezumab, lithium | Indomethacin, verapamil, NSAIDs | Lamotigrine, oxcarbazepine, topiramate, gabapentin | Indomethacin |
SUNCT: Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing
SUNA: Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (Autonomic symptoms: conjunctival injection, tearing, nasal congestion/runny nose, facial sweating, small pupil and/or droopy eyelid, eyelid swelling on affected side).
NSAIDs: nonsteroidal anti-inflammatory drugs.
*Conjuctival injection AND lacrimation (tearing) are present.
**Either conjuctival injection OR lacrimation is present, not both.
***Migraine features may include nausea, vomiting, light/noise sensitivity.
Thu, Apr 24, 25
Clinical Predictors for Efficacy of Erenumab (Aimovig) for Migraine
Discover key predictors of Aimovig (erenumab) response in migraine patients. This REFORM study reveals which patients benefit most from CGRP therapy and why timing matters. Evidence-based insights for better treatment...
Read MoreWed, Apr 23, 25
Effectiveness and Tolerability of Atogepant (Qulipta) in the Prevention of Migraine
STAR study shows atogepant (Qulipta) effectively reduces migraine days by 56.6% in real-world clinical practice, even for patients with previous treatment failures. Learn about this breakthrough.
Read MoreWed, Apr 23, 25
Impact of Visual Stimulus Complexity on Associative Learning in Migraine Patients
Groundbreaking research reveals how migraine patients process visual information differently. This 2025 study found that migraine patients take longer to process simple visual stimuli compared to complex images, which is...
Read More